Importantly, bryostatin 1 has been shown to upregulate CD22 surface expression in ALL, CLL and NHL cells both in vitro and ex vivo26,28,31,37, and in vivo in human clinical trials27,29. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.